<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Altered structure and regulation of the c-myc proto-oncogene have been associated with a variety of human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> and derivative cell lines, including Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, promyelocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> and <z:e sem="disease" ids="C0149925" disease_type="Neoplastic Process" abbrv="SCLC">small cell lung cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCLC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The N-myc gene, first detected by its homology to the second exon of the c-myc gene, is amplified and/or expressed in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> or cell lines derived from <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo>, <z:hpo ids='HP_0009919'>retinoblastoma</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCLC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Here we describe a third myc-related gene (L-myc) cloned from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCLC</z:e> DNA with homology to a small region of both the c-myc and N-myc genes </plain></SENT>
<SENT sid="3" pm="."><plain>Human genomic DNA shows an EcoRI restriction fragment length polymorphism (RFLP) of L-myc defined by two alleles (10.0- and 6.6-kilobase (kb) EcoRI fragments), neither associated disproportionately with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCLC</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Mouse and hamster DNAs exhibit a 12-kb EcoRI L-myc homologue, which indicates conservation of the gene in mammals </plain></SENT>
<SENT sid="5" pm="."><plain>Gene mapping studies assign L-myc to human chromosome region 1p32, a location distinct from that of either c-myc or N-myc but associated with cytogenetic abnormalities in certain human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>This L-myc sequence is amplified 10-20-fold in four <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCLC</z:e> cell line DNAs and in one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCLC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> specimen taken directly from a patient </plain></SENT>
<SENT sid="7" pm="."><plain>Either the 10.0- or 6.6-kb allele can be amplified and in heterozygotes only one of the two alleles was amplified in any <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCLC</z:e> genome </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCLC</z:e> cell lines with amplified L-myc sequences express L-myc-derived transcripts not seen in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCLC</z:e> with amplified c-myc or N-myc genes </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, some <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCLCs</z:e> without amplification also express L-myc-related transcripts </plain></SENT>
<SENT sid="10" pm="."><plain>Together, these findings suggest an enlarging role for myc-related genes in human <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> and provide evidence for the concept of a myc family of proto-oncogenes </plain></SENT>
</text></document>